Company intelligence / Profile preview
BRL Medicine Inc.
Minhang, Shanghai, Chinabrlmed.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
BRL Medicine has multiple programs in clinical trials, with their gene therapy for β-thalassemia showing successful treatment in multiple patients. Their universal CAR-T therapy BRL-303 has successfully treated autoimmune diseases, and their PD1 targeted integration CAR-T product BRL-201 has been approved for IND in China.
- Therapeutic areas
- OncologyImmunologyNeurologyHematology
- Modalities
- Gene TherapyCell TherapyCAR-T TherapyCRISPR-Cas9 Gene Editing
- Industry
- Biotech
02
Drug pipeline
17 assets16 more assets in the full pipeline.
Beyond the preview
Go deeper on BRL Medicine Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRL Medicine Inc..